The recovery pair. One works where you put it, the other works everywhere. Most people who ask this end up running both.
Bottom line: BPC-157 for a specific injury you can point to. TB-500 for whole-body recovery or anything chronic. Both if you can afford it and the injury is stubborn.
| BPC-157 | TB-500 | |
|---|---|---|
| Best for | Localised soft-tissue and gut repair. | Systemic recovery, chronic inflammation, flexibility. |
| Scope | Local. Works best pinned near the injury. | Systemic. Injection site does not matter. |
| Mechanism | Angiogenesis, nitric-oxide modulation, growth-factor receptors on tendon fibroblasts. | Binds G-actin to drive cell migration and tissue remodelling. |
| Reported dose | 250-500 mcg, 1-2× daily. | 2-2.5 mg, twice weekly loading; 2 mg weekly maintenance. |
| Cycle | 4-8 weeks. | 6-12 weeks, then 4 weeks off. |
| Onset | Injury reports cluster at 2-3 weeks. | Slower. 4-6 weeks before most people notice. |
| Oral option | Yes, for gut targets. ~10-20% bioavailability. | No. Injection only. |
| Top side effect | Injection-site welt (18%). Nausea on an empty stomach (7%). | Injection-site irritation (15%). Fatigue for a day after pinning (12%). |
| Evidence tier | Tier 2 · Emerging. One small human study. | Tier 2 · Emerging. Animal data; parent protein in human trials. |
| Common vial | 5 mg. | 5 mg or 10 mg. |
| Reconstitution | 2 mL bac water per 5 mg. | 2 mL bac water per 5 mg. |
| Status | Not approved. FDA Category 1 since Feb 2026, compoundable with Rx. | Not approved. FDA Category 1 since Feb 2026, compoundable with Rx. |
tierA: {"tier":2,"label":"Emerging evidence"}
tierB: {"tier":2,"label":"Emerging evidence"}
summary: Both sit on strong animal data and almost no completed human trials. BPC-157 has one small human knee study. TB-500's parent protein, thymosin beta-4, has been in human trials for wound healing.
trials: [{"name":"Achilles tendon transection, rat","peptide":"a","n":"animal","finding":"Faster tendon-to-bone healing and fibroblast outgrowth with BPC-157 vs control.","pmid":"20698082"},{"name":"Intra-articular BPC-157, knee pain","peptide":"a","n":"12","finding":"Pain relief reported in 11 of 12 at 6 months; open-label, no control.","pmid":"33220100"},{"name":"Thymosin beta-4 wound healing","peptide":"b","n":"animal","finding":"Accelerated dermal wound closure and cell migration via actin binding.","pmid":"10469335"},{"name":"Thymosin beta-4 venous ulcers","peptide":"b","n":"72","finding":"Randomised safety study; healing trend at the mid dose, not powered for efficacy.","pmid":"17495250"}]
{"applies":true,"name":"The Wolverine stack","intro":"They are not competitors. BPC-157 rebuilds locally, TB-500 clears inflammation systemically, so most recovery protocols run both on the same cycle.","phases":[{"name":"Loading","weeks":"Weeks 1-4","a":"250-500 mcg daily, near the injury","b":"2-2.5 mg twice a week"},{"name":"Maintenance","weeks":"Weeks 5-8","a":"250 mcg daily or 5 on / 2 off","b":"2 mg once a week"},{"name":"Off","weeks":"Weeks 9-12","a":"Stop. Reassess the injury.","b":"Stop. Repeat after 4 weeks if needed."}],"note":"Pin them separately. Same site is fine, same syringe is not recommended."}
Yes. It is the most common recovery stack. Run them on the same cycle, pinned separately. No interactions are reported in the literature.
BPC-157. Injury reports cluster at 2-3 weeks. TB-500 needs a 2-4 week loading phase before most people notice anything.
BPC-157 on its own. Add TB-500 if the tendon problem is chronic or there is more than one.
BPC-157, for gut targets only; it survives stomach acid unusually well. TB-500 has no meaningful oral bioavailability.
Yes, both, once reconstituted. 2-8°C, use within 3-4 weeks. Lyophilised powder tolerates room temperature during shipping.
Both are WADA-prohibited in and out of competition. If you are tested, do not use either.
Roughly $40 a month for BPC-157, $75 for TB-500, $115 for both, before the kit.
A 30G, 0.5 inch, 1 mL insulin syringe for both. Reconstitute with 2 mL bacteriostatic water per 5 mg vial.
These statements have not been evaluated by the FDA. This content is for educational purposes only. Consult a healthcare professional before starting any protocol. vialprep sells injection supplies, not compounds.
